ABL1 and myelodysplastic syndrome: Mutational status for other myeloid diseases must be evaluated and negative including theBCR-ABL, i.e. “the Philadelphia chromosome”, and fluorescence in situ hybridization (FISH) for myelodysplastic syndrome (MDS) panel to exclude the diagnosis of CML and MDS, respectively (seeTable 2)2.